Sara Viganò

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Results from part A of the multi-center, double-blind, randomized, placebo-controlled NefIgArd trial, which evaluated targeted-release formulation of budesonide for the treatment of primary immunoglobulin A nephropathy

Jonathan Barratt, Richard Lafayette, Jens Kristensen et al. · Kidney International · 2022 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

LONG-TERM OUTCOME OF VESICOURETERAL REFLUX ASSOCIATED CHRONIC RENAL FAILURE IN CHILDREN. DATA FROM THE ITALKID PROJECT

Gianluigi Ardissino, Luigi Avolio, Valeria Daccò et al. · The Journal of Urology · 2004 · 80 citations

Puberty is associated with increased deterioration of renal function in patients with CKD: data from the ItalKid Project

Gianluigi Ardissino, Sara Testa, Valeria Daccò et al. · Archives of Disease in Childhood · 2012 · 72 citations